Cargando…

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling

Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction, which may underlie the hampered efficacy of cellular immunotherapy. Most data on dampened immune responses in CLL come from studies investigating CLL and T cell interactions. Natural killer (NK) cells may be an at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofland, Tom, Endstra, Sanne, Gomes, Calum K.P., de Boer, Renate, de Weerdt, Iris, Bobkov, Vladimir, Riedl, Jurgen A., Heukers, Raimond, Smit, Martine J., Eldering, Eric, Levin, Mark-David, Kater, Arnon P., Tonino, Sanne H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924557/ https://www.ncbi.nlm.nih.gov/pubmed/31976482 http://dx.doi.org/10.1097/HS9.0000000000000308

Ejemplares similares

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019)

Functional Differences Between EBV- and CMV-Specific CD8(+) T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
por: Hofland, Tom, et al.
Publicado: (2020)

Human CXCR5(+)PD‐1(+) CD8 T cells in healthy individuals and patients with hematologic malignancies
por: Hofland, Tom, et al.
Publicado: (2020)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
por: de Weerdt, Iris, et al.
Publicado: (2019)

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
por: van Bruggen, Jaco A. C., et al.
Publicado: (2020)

Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837
por: van Bruggen, Jaco A. C., et al.
Publicado: (2021)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
por: Haselager, Marco V., et al.
Publicado: (2020)

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
por: Jacobs, Chaja F., et al.
Publicado: (2021)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
por: van Attekum, Martijn HA, et al.
Publicado: (2017)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
por: de Weerdt, Iris, et al.
Publicado: (2017)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
por: Peters, Fleur S., et al.
Publicado: (2021)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Circumventing the Greatwall
por: Short, Ben
Publicado: (2014)

Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists
por: Işbilir, Ali, et al.
Publicado: (2020)

Bench-to-bedside review: Preventive measures for contrast-induced nephropathy in critically ill patients
por: van den Berk, Guido, et al.
Publicado: (2005)

Hypo and Hyperthyroidism
por: Hixson, J. S.
Publicado: (1915)

Circumventing Zygotic Lethality to Generate Maternal Mutants in Zebrafish
por: Shi, De-Li
Publicado: (2022)

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
por: Kater, Arnon P., et al.
Publicado: (2018)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Montironi, Chiara, et al.
Publicado: (2023)

Cases of Hypo-Thyroidism
por: Milne, C.
Publicado: (1914)

Hypo-Substitute for Opiates
Publicado: (1899)

Fellows’ Hypo Phosphites
Publicado: (1880)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Circumventing the stability problems of graphene nanoribbon zigzag edges
por: Lawrence, James, et al.
Publicado: (2022)

S66. USING UNITIZATION TO CIRCUMVENT RELATIONAL MEMORY DEFICITS IN SCHIZOPHRENIA
por: de Sousa, Ana Elisa Farias, et al.
Publicado: (2020)

P595: DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Simon-Molas, Helga, et al.
Publicado: (2023)

Hypo-osmolality in beer drinkers
por: Hilden, Tage, et al.
Publicado: (1975)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Designing malaria vaccines to circumvent antigen variability()
por: Ouattara, Amed, et al.
Publicado: (2015)

How Dengue Virus Circumvents Innate Immunity
por: Kao, Yu-Ting, et al.
Publicado: (2018)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies
por: Soave, Mark, et al.
Publicado: (2020)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

Fluorescently tagged nanobodies and NanoBRET to study ligand-binding and agonist-induced conformational changes of full-length EGFR expressed in living cells
por: Comez, Dehan, et al.
Publicado: (2022)

Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer
por: Tiwary, Richa, et al.
Publicado: (2011)

Hypo, hype and ‘hyp’ human proteins
por: Suravajhala, Prashanth
Publicado: (2007)

Concomitant hypo-hyperdontia with an endocrine etiology
por: Surendran, Sharmila, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hrq0c0hj9nutt51oqalh1o3b4o